MEDIUM confidence: 100% data completeness, but the composite (44) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Low explanatory power (R² 0.10) — the factor model explains little of this stock's return variation, so these exposures are noisy. Interpret with caution.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-19.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Avg target $119 (last qtr, 5 analysts) → $122 (last mo, 3) (+2.2%).
Buy-rated share 71% → 75% over ~3 months (+4pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jul 2026 | $0.02 | $0.36 | +1383.3% |
| Apr 2026 | $-0.11 | $-0.30 | -172.3% |
| Feb 2026 | $0.33 | $0.20 | -39.4% |
| Nov 2025 | $0.18 | $0.16 | -11.1% |
| Jul 2025 | $0.23 | $0.29 | +26.1% |
| May 2025 | $0.17 | $0.17 | +0.0% |
| Feb 2025 | $0.37 | $0.26 | -29.7% |
| Oct 2024 | $0.28 | $0.41 | +46.4% |
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $366M— | $402M+9.8% | $482M+20.0% | $675M+39.9% | $761M+12.8% |
| EPS (dil.) | $0.89— | $0.87-2.2% | $0.94+8.0% | $1.23+30.9% | $0.82-33.3% |
| Free Cash Flow | $167M— | $120M-28.4% | $127M+5.8% | $196M+54.4% | $142M-27.6% |
| Gross Margin | 98.6% | 98.7%+0.1pp | 98.7%-0.0pp | 98.4%-0.3pp | 98.3%-0.1pp |
| Operating Margin | 34.0% | 28.0%-6.0pp | 22.2%-5.8pp | 20.3%-2.0pp | 5.9%-14.4pp |
| Net Margin | 30.7% | 25.2%-5.5pp | 22.0%-3.2pp | 20.7%-1.3pp | 13.1%-7.6pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Net insider -$40.4M over 180 days (0 open-market buys, 47 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth below the analyst consensus of 32.7%/yr (revenue basis).
Base free cash flow $155M (avg FY2023–FY2025; latest year $142M) · equity value $12.0B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
The QScore of 44 for Corcept Therapeutics indicates a neutral outlook, driven by a divergence between its long-term and short-term scores. The stock scores high on momentum, exhibiting strong price appreciation of 51% over the past year and 94.7% over the past three months. However, it trades at a premium, with a P/E of 213.3 and EV/EBITDA of 413.0, which weighs down its value score, while its growth score is also impacted by negative EPS and FCF growth.